Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial

Matarrelli, Barbara; Vitacolonna, Ester; D’Angelo, Matteo; Pavone, G.; Mattei, Peter A.; Liberati, Marco; Celentano, Claudio

doi:10.3109/14767058.2013.766691

Cited by 97 publications

(114 citation statements)

References 14 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Also Matarrelli et al found similar results conducting a prospective, randomized, double-blinded, placebo-controlled clinical trial [19]. They enrolled 84 non-obese singleton pregnant women with an elevated fasting glucose in the first or early second trimester randomizing them to receive either MI or placebo.…”

Section: Inositol As a Therapeutic Option To Prevent Gdmsupporting

confidence: 48%

See 1 more Smart Citation

The Prevention of Gestational Diabetes

Cagnazzo¹,

Caserta²

2013

J Diabetes Metab

View full text Add to dashboard Cite

The negative impact of the gestational diabetes on the maternal and fetal health is well known and this impact is closely related to gestational age at which the diagnosis is done. Therefore, the use of therapeutic options able to prevent or delay the gestational diabetes occurrence has a positive impact on maternal and neonatal outcomes.Physical activity and dietary advice represent the first choice and they are the most studied as well. They represent a non-pharmacological option and have a positive impact on insulin resistance although they do not seem to prevent the gestational diabetes onset.The preconceptional use of metformin in women with polycystic ovary syndrome protects the pancreatic beta cell reserve preventing or delaying the occurrence of gestational diabetes. However, there are also doubts on the drug safety in pregnancy since it completely crosses the placenta.From this point of view, the inositol could represent an excellent alternative.Its role as insulin sensitizing agent is well documented on improving both the hormonal and reproductive parameters. However, the studies on its preconceptional use in preventing gestational diabetes are too limited though the first results are extremely encouraging.

show abstract

Section: Inositol As a Therapeutic Option To Prevent Gdmsupporting

confidence: 48%

“…Considering the insulin-mimetic effect of inositol supplementation in several animal models of insulin resistance [12][13][14] and in women with polycystic ovary syndrome (PCOS) [15], it has been recently hypothesized and studied its positive on the GDM incidence [16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

The Prevention of Gestational Diabetes

Cagnazzo¹,

Caserta²

2013

J Diabetes Metab

View full text Add to dashboard Cite

show abstract

“…26 Özellikleri nedeni ile, inositol tedavisinin gestasyonel diabetes mellitus (GDM) için etkili bir tedavi olduğu dü-şünülmektedir. 27 MI tedavisinin ailede Tip 2 diyabet öyküsü olan gebelerde GDM başlangıcını azaltıp azaltmadığını değerlendiren çalışmada, gebeliğinin 1. trimesterinde olan bireyler iki farklı gruba ayrılmıştır. Birinci gruba (n=110) 2 g MI ve 200 µg FA verilirken ikinci gruba (n=110) plasebo ve yalnızca FA günde iki kez verilmiştir.…”

Section: Gestasyonel Di̇abetes Melli̇tusunclassified

“…24 Yapılan başka bir çalışmada MI alan grupta gestasyonel diyabet insidansının plasebo alan gruba göre daha düşük olduğu bulunmuştur (p=0,001). 27 MI'nın GDM'de insülin direnci ve duyarlılığı üzerinde etkisini araştıran çalışmada araştırma grubuna (n=24) günde 4 g MI ve 400 µg FA verilirken kontrol grubuna (n=45) yalnızca 400 µg FA verilmiştir. Araştırma sonunda MI+FA alan grupta açlık kan glukozu, insülin düzeyi ve insülin direncinin diğer gruba göre daha düşük olduğu bulunmuştur.…”

Section: Gestasyonel Di̇abetes Melli̇tusunclassified

Inositol and Women Reproductive Health

Elibol¹,

Akdevelioğlu²

2017

Turkiye Klinikleri J Health Sci

View full text Add to dashboard Cite

show abstract

“…Megállapították, hogy mio-inozitol alkalmazásával az anyáknál csökkent az inzulinigény, és az anyák későbbi terhességi hétben szültek. A született magzatok adatait elemezve azt észlelték, hogy a készít-mény alkalmazásakor az újszülötteknél a macrosomia, valamint a születés utáni hypoglykaemia ritkább volt [23].…”

Section: Táblázatunclassified

A mio-inozitol jótékony hatása inzulint igénylő 2-es típusú cukorbetegséghez társuló polycystás ovarium szindrómás várandós terápiájában

Kun

Tornóczky

2017

Orvosi Hetilap

View full text Add to dashboard Cite

A szerzők a mio-inozitol hatását mutatják be egy 2-es típusú diabetes mellitusban szenvedő, inzulinkezelést is igény-lő, egyben polycystás ovarium szindrómás (PCOS) várandósnál. A betegnek korábban inzulinkezelés és metformin adása mellett sem volt egyensúlyban a szénhidrátháztartása, hypoglykaemiás rosszullétei gyakoriak voltak. Mio-inozitol és folsav étrendkiegészítő-adás megkezdésével szénhidrátháztartása javult, két hónap múlva várandós lett. A vá-randósság 19. terhességi hetében inkomplett vetélése zajlott. A magzat kórboncolása során a patológus nem talált fejlődési rendellenességet. E terápia mellett a beteg később újból várandós lett, és 29 hetesen egy koraszülöttnek adott életet. Az esetbemutatás arra kívánja felhívni a figyelmet, hogy a mio-inozitol-tartalmú étrend-kiegészítő haté-konyabbá teheti a cukorbetegség kezelését. Orv. Hetil., 2017, 158(14), 541-545. Kulcsszavak: inzulint igénylő 2-es típusú cukorbetegség, polycystás ovarium szindróma, várandósságThe myo-inositol is beneficial in the therapy of pregnancy with insulindependent type 2 diabetes and polycystic ovary syndromeAuthors would like to demonstrate the beneficial effect of myo-inositol supplementation in a pregnant woman with insulin-dependent type 2 diabetes mellitus and polycystic ovary syndrome. Insulin and metformin treatment could not achieve normalization of glucose homeostasis for 3 years, and hypoglycemic episodes were frequent. Myo-inositol and folic acid supplementation added to the basic treatment resulted in improved glucose levels in 2 months. At this time she became pregnant. During pregnancy serum glucose levels still improved in the next 2 months. The amniotic membrane ruptured at the 19th gestational week, and pregnancy had to be finished. Developmental disturbances were excluded by the pathologist. She became pregnant again and gave birth to a premature male neonate at the 29th gestational week. The aim of the report was to demonstrate that myo-inositol supplementation may improve the efficacy of the therapy in type 2 diabetes mellitus.Keywords: insulin-dependent type 2 diabetes, polycystic ovary syndrome, pregnancy Kun, A., Tornóczky, J. [The myo-inositol is beneficial in the therapy of pregnancy with insulin-dependent type 2 diabetes and polycystic ovary syndrome]. Orv. Hetil., 2017, 158(14), 541-545. ESETISMERTETÉSRövidítések BMI = (body mass index) testtömegindex; FSH = folliculusstimuláló hormon; GADA = glutaminsav-dekarboxiláz-ellenes antitest; GDM = (gestational diabetes mellitus) terhességi cukorbetegség; IAA = inzulin-autoantitestek, ICA = (islet cell antibodies) szigetsejtellenes antitestek; LADA = (latent autoimmun diabetes in adults) latens felnőttkori autoimmun diabetes mellitus; LH = luteinizáló hormon; PCOS = (polycystic ovar syndrome) polycystás ovarium szindróma; SHGB = (sex hormone-binding globulin) nemihormon-kötő szérumfehérje; TSH = (thyroid-stimulating hormone) pajzsmirigyműködést serkentő hormon

show abstract

Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial

Abstract: Myo-inositol supplementation in pregnancy reduced the incidence of GDM in women at high risk of this disorder. The reduction in incidence of GDM in the treatment arm was accompanied by improved outcomes.

Cited by 97 publications

References 14 publications

The Prevention of Gestational Diabetes

The Prevention of Gestational Diabetes

Inositol and Women Reproductive Health

A mio-inozitol jótékony hatása inzulint igénylő 2-es típusú cukorbetegséghez társuló polycystás ovarium szindrómás várandós terápiájában

Contact Info

Product

Resources

About